Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
By R. Schrier, P. Gross, M. Gheorghiade, T. Berl, J. Verbalis, F. Czerwiec, C. Orlandi. New England Journal of Medicine, 2006
1,194 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/03c7bf3ae4b2e38925cc612da5fc71d1372a76ec
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Molecular Biology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Clinical practice guideline on diagnosis and treatment of hyponatraemia. (2014, positive): “We identified five additional trials published since 2010, increasing the total sample size to 20 trials and 2900 participants [179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197].”
- Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (2007, background): “Tolvaptan was also recently demonstrated to safely treat hyponatremia of diverse origin.(15) The Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) program evaluated the effects of tolvaptan on clinical status, morbidity, and mortality in patients hospitalized”
- Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 (2013, background): “An oral preparation — tolvaptan — increases serum sodium in patients who have pretreatment values of <130 mmol/L.(60) Hyponatremia recurs when this drug is discontinued.”
- Acute heart failure syndromes (2009, background): “, tolvaptan and conivaptan) ffectively correct hyponatremia, their use has not been assoiated with improved outcomes (43,60,96).”
- Management of adult patients with ascites due to cirrhosis (2004, background): “An oral preparation — tolvaptan — increases serum sodium in patients who have pretreatment values of <130 mmol/L.(60) Hyponatremia recurs when this drug is discontinued.”